Form 4: CRISPR CFO Exercises Options, Sells Shares in Planned Trade
Insider Transaction Report
CRISPR Therapeutics' CFO, Raju Prasad, exercised stock options and subsequently sold a portion of the acquired common shares under a pre-arranged trading plan.
Summary
- Raju Prasad, Chief Financial Officer of CRISPR Therapeutics AG (CRSP), reported transactions on January 22, 2026.
- Prasad exercised stock options to acquire 34,972 common shares at an exercise price of $45.15 per share.
- Concurrently, Prasad sold 34,972 common shares at a weighted average price of $60.19 per share, with individual sales ranging from $60.00 to $60.42.
- These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2025.
- Following these transactions, Prasad directly beneficially owns 6,767 common shares.
- Prasad also holds 41,667 stock options (right to buy) with an exercise price of $45.15, which were granted on March 14, 2023, and vest over time.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While an insider sale can sometimes be viewed negatively, the transaction involves the exercise of options and a pre-planned sale under a 10b5-1 plan, which is a common and regulated practice for executives to manage their equity compensation and personal finances. It reflects the executive realizing value from their compensation.
Positives
- The Chief Financial Officer realized value from previously granted stock options, indicating a personal financial gain from company performance.
- The sale was conducted under a Rule 10b5-1 trading plan, which demonstrates pre-planning and adherence to insider trading regulations, reducing concerns about opportunistic selling.
Negatives
- The transaction resulted in a reduction of the Chief Financial Officer's direct beneficial ownership of common shares, which some investors might interpret as a lack of confidence, despite the pre-planned nature.
Future Outlook
na
Industry Context
This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Adoption | Raju Prasad adopted a Rule 10b5-1 trading plan on August 18, 2025, which pre-schedules the sale of equity securities to comply with insider trading laws. | 08/18/2025 | This demonstrates adherence to corporate governance best practices regarding insider trading, providing a legal framework for executives to sell shares without being accused of trading on material non-public information. |
Stakeholder Impact
- Shareholders: May observe the CFO's decision to realize value from stock options and reduce direct share ownership, which could be interpreted in various ways depending on individual investment strategies and market sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/14/2023 | Date stock option for 100,000 Common Shares was granted to Raju Prasad. |
| 03/14/2024 | First vesting date for 25% of the granted stock options. |
| 08/18/2025 | Date Raju Prasad adopted the Rule 10b5-1 trading plan. |
| 01/22/2026 | Date of stock option exercise and subsequent sale of common shares. |
| 01/26/2026 | Date the Form 4 was signed by Elizabeth Ryland Waldinger, attorney-in-fact. |
| 03/14/2033 | Expiration date of the stock options. |
Keywords
CRISPR Therapeutics, CRSP, Form 4, Insider Trading, Stock Option Exercise, Share Sale, CFO, Rule 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.